Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Mechanism of Action:** This compound is a small molecule inhibitor of methionine aminopeptidase (MAP), an enzyme involved in the removal of N-terminal methionine from nascent proteins. Inhibition of MAP can affect protein maturation and function[6][8]. The drug is currently experimental and has not been approved for any therapeutic indication. **Additional Information:** The compound is a solid belonging to the benzene and substituted derivatives class. It has been studied primarily as a research tool for understanding methionine aminopeptidase function in bacteria such as Escherichia coli[6][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 5-imino-4-(3-trifluoromethyl-phenylazo)-5H-pyrazol-3-ylamine.